SAGE-217 in subjects with major depressive disorder: Efficacy and safety results from open-label Part A of a phase 2A study

Authors
Category Primary study
JournalEuropean Neuropsychopharmacology
Year 2017
This article has no abstract
Epistemonikos ID: 18de714edba5fb0093c5b319454819e24f4bc20f
First added on: Feb 08, 2025